Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.